MEDAL: Effect on thrombotic CV endpoints

1
MEDAL Effect on thrombotic CV endpoints
Multinational Etoricoxib and Diclofenac Arthritis
Long-term program
7.0
6.0
5.0
Cumulativeincidence()
4.0
3.0
2.0
1.0
0
0
6
1
2
1
8
2
4
3
0
3
6
42
Months
Number at risk
Etoricoxib
16,819
13,359
10,733
8277
6427
4204
805
Dicloflenac
16,483
12,800
10,142
7901
6213
3832
815
Diclofenac
Etoricoxib
Primary outcome includes fatal/nonfatal cardio-,
cerebro-, and peripheral vascular events
Cannon CP et al. Lancet. 2006.